Toxicology Reports
October 11, 2016
Michael T. Williams, Matthew R. Skelton, Ian D. Longacre et al.
3 citations
The abuse of methylenedioxymethamphetamine (MDMA) during pregnancy is of concern. MDMA treatment of rats during a period of brain growth analogous to late human gestation leads to neurochemical and behavioral changes. MDMA from postnatal day (P)11–20 in rats produces reductions in serotonin and deficits in spatial and route-based navigation. In this experiment we examined the impact of MDMA...
The International Journal of Neuropsychopharmacology
January 11, 2013
Tori L. Schaefer, Curtis E. Grace, A Braun et al.
24 citations
Abstract We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) treatment induces long-term spatial and egocentric learning and memory deficits and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic factor influencing neurogenesis, synaptogenesis, migration, and target field organization. MDMA (10 mg/kg × 4/d at 2 h intervals) given on...
The International Journal of Neuropsychopharmacology
June 28, 2011
Matthew R. Skelton, Devon L. Graham, Tori L. Schaefer et al.
8 citations
Previous findings showed allocentric and egocentric learning deficits in rats after MDMA treatment from postnatal days (PD) 11-20 but not after treatment from PD 1-10. Shorter treatment periods (PD 1-5, 6-10, 11-15, or 16-20) resulted in allocentric learning deficits averaged across intervals but not for any interval individually and no egocentric learning deficits individually or collectively....
Synapse
October 8, 2010
Charles V. Vorhees, Elizabeth He, Matthew R. Skelton et al.
(+)‐Methamphetamine (MA), (±)‐3,4‐methylenedioxymethamphetamine (MDMA), (+)‐amphetamine (AMPH), and (±)‐fenfluramine (FEN) are phenylethylamines with CNS effects. At higher doses, each induces protracted reductions in brain dopamine (DA) and/or serotonin. Chronic MA and MDMA users show persistent monoamine reductions and cognitive impairments. In rats, similar neurochemical effects can be...
Psychopharmacology
June 1, 2009
Matthew R. Skelton, Tori L. Schaefer, Nicole R Herring et al.
31 citations
We have previously shown that (+/-)-3,4-methylenedioxymethamphetamine (MDMA) treatment from postnatal days (P)11 to P20 leads to learning and memory deficits when the animals are tested as adults. Recently, the club drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has gained popularity. Due to the similarities between MDMA and 5-MeO-DIPT and the substitution of 5-MeO-DIPT for MDMA, the...
Developmental Neuroscience
2009
Charles V. Vorhees, Tori L. Schaefer, Matthew R. Skelton et al.
40 citations
During postnatal days (PD) 11–20, (+/–)3,4-methylenedioxymethamphetamine (MDMA) treatment impairs egocentric and allocentric learning, and reduces spontaneous locomotor activity; however, it does not have these effects during PD 1–10. How the learning impairments relate to the stress hyporesponsive period (SHRP) is unknown. To test this association, the preweaning period was subdivided into...
Neuropharmacology
December 2008
Matthew R Skelton, Jessica A Able, Curtis E Grace et al.
3,4-Methlylenedioxymethamphetamine (MDMA) administration (4 x 15 mg/kg) on a single day has been shown to cause path integration deficits in rats. While most animal experiments focus on single binge-type models of MDMA use, many MDMA users take the drug on a recurring basis. The purpose of this study was to compare the effects of repeated single-day treatments with MDMA (4 x 15 mg/kg) once...
International Journal of Developmental Neuroscience
August 1, 2004
Charles V. Vorhees, Tracy M. Reed, Matthew R. Skelton et al.
76 citations
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) in previous experiments has been shown to induce long‐term spatial and sequential learning and memory deficits in adult offspring after exposure to the drug on postnatal (P) days 11–20, but not after exposure on P1–10. Herein we further tested for the effects of MDMA (0, 5, 10 or 20 mg/kg × 2/day) after exposure on P11–20 on reference and...